Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients

References

• Charytan DM, Pai AB, Chan CT, et al. Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol. 2015;26:1238–1247.
   PubMed Web of Science ®Google Scholar
• Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590.
   PubMed Web of Science ®Google Scholar
• Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084.
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098.
   PubMed Web of Science ®Google Scholar
• Wetmore JB, Peng Y, Monda KL, et al. Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: A retrospective cohort analysis. Am J Nephrol. 2015;41:354–361.
   PubMed Web of Science ®Google Scholar
• Rhee CM, Kalantar-Zadeh K. Is iron maintenance therapy better than load and hold? J Am Soc Nephrol. 2013;24:1028–1033.
   PubMed Web of Science ®Google Scholar
• Freburger JK, Ellis AR, Kshirsagar AV, Wang L, Brookhart MA. Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: A replication study. BMC Nephrol. 2014;15:154–163.
   PubMed Web of Science ®Google Scholar
• KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease, Kidney Int Suppl. 2012;2:279–335.
   Google Scholar
• Locatelli F, Bárány P, Covic A, et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: A European renal best practice position statement. Nephrol Dial Transplant. 2013;28:1346–1359.
   PubMed Web of Science ®Google Scholar
• Susantitaphong P, Alqahtani F, Jaber BL. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: A meta-analysis. Am J Nephrol. 2014;39:130–141.
   PubMed Web of Science ®Google Scholar
• Bailie GR, Larkina M, Goodkin DA, et al. Variation in intravenous iron use internationally and over time: The dialysis outcomes and practice patterns study (DOPPS). Nephrol Dial Transplant. 2013;28:2570–2579.
   PubMed Web of Science ®Google Scholar
• Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011;3:12–33.
   Google Scholar
• Vos FE, Schollum JB, Coulter CV, Doyle TC, Duffull SB, Walker RJ. Red blood cell survival in long-term dialysis patients. Am J Kidney Dis. 2011;58:591–598.
   PubMed Web of Science ®Google Scholar
• Krzyzanski W, Brier ME, Creed TM, Gaweda AE. Reticulocyte-based estimation of red blood cell lifespan. Exp Hematol. 2013;41:817–822.
   PubMed Web of Science ®Google Scholar
• Lorenzo JD, Rodríguez MM, Martín SS, Romo JM. Assessment of erythropoiesis activity during hemodialysis therapy by soluble transferrin receptor levels and ferrokinetic measurements. Am J Kidney Dis. 2001;37:550–556.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Pootrakul P, Huebers HA, Eng M, Eschbach J, Finch CA. Erythroid marrow function in anemic patients. Blood. 1987;69:296–301.
   PubMed Web of Science ®Google Scholar
• Thomas DW, Hinchliffe RF, Briggs C, et al. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol. 2013;161:639–648.
   PubMed Web of Science ®Google Scholar
• Ferrari P, Dheda S, Betti S, et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:77–83.
   PubMed Web of Science ®Google Scholar
• Besarab A, Szczech L. Uses and interpretation of iron studies in patients on chronic dialysis. Semin Dial. 2014;27:579–581.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Geisser P. Use of intravenous iron supplementation in chronic kidney disease: An update. Iran J Kidney Dis. 2013;7:9–22.
   PubMed Web of Science ®Google Scholar
• Bailie GR, Larkina M, Goodkin DA, et al. Data from the dialysis outcomes and practice patterns study validate an association between high intravenous iron doses and mortality. Kidney Int. 2015;87:162–168.
   PubMed Web of Science ®Google Scholar
• Miskulin DC, Tangri N, Bandeen-Roche K, et al. Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol. 2014;9:1930–1939.
   PubMed Web of Science ®Google Scholar
• Fishbane S, Mathew AT, Wanchoo R. Intravenous iron exposure and outcomes in patients on hemodialysis. Clin J Am Soc Nephrol. 2014;9:1837–1839.
   PubMed Web of Science ®Google Scholar
• Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102:783–788.
   PubMed Web of Science ®Google Scholar
• Tsuchiya K, Nitta K. Hepcidin is a potential regulator of iron status in chronic kidney disease. Ther Apher Dial. 2013;17:1–8.
   PubMed Web of Science ®Google Scholar
• Zaritsky J, Young B, Wang HJ, et al. Hepcidin-a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1051–1056.
   PubMed Web of Science ®Google Scholar
• Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75:976–981.
   PubMed Web of Science ®Google Scholar
• Gaweda AE, Ginzburg YZ, Chait Y, Germain MJ, Aronoff GR, Rachmilewitz E. Iron dosing in kidney disease: Inconsistency of evidence and clinical practice. Nephrol Dial Transplant. 2015;30:187–196.
   PubMed Web of Science ®Google Scholar
• van der Weerd NC, Grooteman MP, Bots ML, CONTRAST Investigators, et al. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant. 2013;28:3062–3071.
   PubMed Web of Science ®Google Scholar